This result was particularly significant for patients cotreated with megestrol acetate.

Ongoing studies have been designed to better study the appetite-enhancing effects of megestrol acetate.

Aim: To study the impurity in the drug megestrol acetate.

Our objective was to evaluate the antiemetic ability of megestrol acetate in patients receiving chemotherapy.

Results: Two new epimers were isolated from the mother liquid of the drug megestrol acetate.

Like the cortisones, megestrol acetate actually increases appetite, can increase risk of respiratory infections, and may suppress adrenal function.

This study determined whether an EPA supplement-administered alone or with megestrol acetate (MA)-was more effective than MA.

The incidence of adrenal suppression was affected by age, performance status, stage, and use of megestrol acetate in univariate analysis.

The positive dose-response effect observed for megestrol acetate on appetite stimulation supports both the prestudy hypothesis and findings in the literature.

The data demonstrate a positive dose-response effect for megestrol acetate on appetite stimulation (p = 0.02).

Interestingly, ten of 12 patients who had developed disease progression while on standard-dose megestrol acetate therapy had objective response or stabilization on the higher dose.

Megestrol acetate might be a new antiemetic option for chemotherapy.

Megestrol acetate was well tolerated in this group of patients with advanced malignant disease.

Megestrol acetate (MA) is used to stimulate appetite in children with cancer, but it can impair adrenal function and cause adrenal insufficiency.

Megestrol acetate (Megace, Bristol-Myers Squibb Co.) proves so far the most effective pharmacological preparation which improves anorexia and cachexia in severely ill patients.

This result was particularly significant for patients cotreated with megestrol acetate.